Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery

Axol Bioscience Ltd. announced that its hiPSC-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.
[Axol Bioscience Ltd (THE SCIENTIST)]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News